恶性腹膜间皮瘤临床分析
Clinical Analysis of Malignant Peritoneal Mesothelioma
DOI: 10.12677/ACM.2024.142645, PDF,   
作者: 宋文静, 张雯丽, 崔紫程, 单玉萍:青岛大学医学部,山东 青岛;陈爱平*:青岛大学附属医院,妇科,山东 青岛
关键词: 恶性腹膜间皮瘤免疫组织化学CRS + HIPEC治疗预后Malignant Peritoneal Mesothelioma Immunohistochemistry CRS + HIPEC Treatment Prognosis
摘要: 目的:探讨恶性腹膜间皮瘤(malignant peritoneal mesothelioma, MPM)的临床病理特点、诊断、治疗及预后。方法:收集青岛大学附属医院2015年至2023年于我院治疗的11例MPM患者临床资料,进行回顾性研究。结果:11例MPM患者,发病年龄为30~81岁,其中1例患者存在石棉暴露史。临床表现主要为腹胀及腹痛。初次治疗时4例患者CA125水平升高,余7例患者CA125正常,其PCI评分为3~29分。所有患者均行手术治疗,并据患者病情术后选择不同的辅助治疗,9例接受化疗,1例观察,失访1例。本研究患者总随访时间为4~53个月,存活4人。结论:MPM临床症状及影像学缺乏特异性,其诊断需依赖病理及免疫组织化学结果,确诊后治疗方案首选肿瘤细胞减灭术(cytoreductive surgery, CRS)联合腹腔热灌注化疗(hyperthermic intraperitoneal chemotherapy, HIPEC),术后以培美曲塞联合顺铂为一线化疗方案,MPM预后差,组织学亚型及腹膜癌指数评分(peritoneal cancer index, PCI)与其预后密切相关。
Abstract: Objective: To discuss the clinical characteristics, pathological characteristics, diagnosis, treatment and prognosis of malignant peritoneal mesothelioma. Methods: The clinical data of 11 patients with MPM who were treated in the Affiliated Hospital of Qingdao University from 2015 to 2023 were col-lected for retrospective study. Results: Eleven patients with MPM were diagnosed at the onset of 30-81 years and one patient had a history of asbestos exposure. The clinical manifestations were mainly abdominal distension and abdominal pain. During the initial treatment, 4 patients had ele-vated CA125 levels, and the remaining 7 patients had normal CA125, and their PCI score was 3~29. All patients underwent surgery and chose different adjuvant therapy according to their condition, 9 received chemotherapy, 1 underwent observation and 1 was lost to follow-up. The total follow-up time of patients was 4~53 months in this study, with 4 people alive. Conclusion: Because of the lack of specificity of the clinical symptoms and imaging findings of MPM, Its diagnosis depends on patho-logical and immunohistochemical results. Treatment options are preferred cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy after diagnosis. The first-line chemo-therapy is pemetrexed and cisplatin. MPM has a poor prognosis, Histological subtype and the index score of peritoneal carcinoma is closely related to its prognosis.
文章引用:宋文静, 张雯丽, 崔紫程, 单玉萍, 陈爱平. 恶性腹膜间皮瘤临床分析[J]. 临床医学进展, 2024, 14(2): 4656-4662. https://doi.org/10.12677/ACM.2024.142645

参考文献

[1] Kusamura, S., Kepenekian, V., Villeneuve, L., et al. (2021) Peritoneal Mesothelioma: PSOGI/EURACAN Clinical Prac-tice Guidelines for Diagnosis, Treatment and Follow-Up. European Journal of Surgical Oncology, 47, 36-59. [Google Scholar] [CrossRef] [PubMed]
[2] Kaya, H., Sezgı, C., Tanrıkulu, A.C., et al. (2014) Prognostic Fac-tors Influencing Survival in 35 Patients with Malignant Peritoneal Mesothelioma. Neoplasma, 61, 433-438. [Google Scholar] [CrossRef] [PubMed]
[3] Yan, T.D., Hassan, R., Welch, L. and Sugarbaker, P.H. (2007) Ad-vances in Diffuse Malignant Peritoneal Mesothelioma. Oncology Reviews, 1, 53-64. [Google Scholar] [CrossRef
[4] Salo, S.A.S., Lantto, E., Robinson, E., Myllärniemi, M., Laak-sonen, S., Salo, J.A., Rantanen, T. and Ilonen, I. (2020) Prognostic Role of Radiological Peritoneal Cancer Index in Ma-lignant Peritoneal Mesothelioma: National Cohort Study. Scientific Reports, 10, Article No. 13257. [Google Scholar] [CrossRef] [PubMed]
[5] Carbone, M., Adusumilli, P.S., Alexander, H.R., et al. (2019) Mesothelioma: Scientific Clues for Prevention, Diagnosis, and Therapy. CA: A Cancer Journal for Clinicians, 69, 402-429. [Google Scholar] [CrossRef] [PubMed]
[6] 曾艳, 童瑞, 王翔耀, 等. 恶性腹膜间皮瘤26例临床特点及预后影响因素分析[J]. 解放军医学院学报, 2015, 36(6): 559-562, 567.
[7] 中国抗癌协会腹膜肿瘤专业委员会, 中国抗癌协会肿瘤热疗专业委员会, 北京癌症防治学会肿瘤热疗专业委员会. 弥漫性恶性腹膜间皮瘤诊治中国专家共识[J]. 中华医学杂志, 2021, 101(36): 2839-2849.
[8] Baratti, D., Kusamura, S. and Deraco, M. (2009) Cir-culating CA125 and Diffuse Malignant Peritoneal Mesothelioma. European Journal of Surgical Oncology, 35, 1198-1199. [Google Scholar] [CrossRef] [PubMed]
[9] Bruno, F., Baratti, D., Martinetti, A., Morelli, D., Sot-totetti, E., Bonini, C., Guaglio, M., Kusamura, S. and Deraco, M. (2018) Mesothelin and Osteopontin as Circulating Markers of Diffuse Malignant Peritoneal Mesothelioma: A Preliminary Study. European Journal of Surgical Oncology, 44, 792-798. [Google Scholar] [CrossRef] [PubMed]
[10] Marchevsky, A.M. (2008) Application of Immuno-histochemistry to the Diagnosis of Malignant Mesothelioma. Archives of Pathology & Laboratory Medicine, 132, 397-401. [Google Scholar] [CrossRef
[11] 杜雪梅, 昌红, 李雁. 恶性腹膜间皮瘤临床病理进展[J]. 临床与实验病理学杂志, 2021, 37(4): 441-445.
[12] Tohumcuoglu, M., Büyüksimsek, M., Kara, I.O., et al. (2019) The Prognostic Analysis of the Some Clinicopathological Parameters and Gene Protein Expressions in Malignant Mesothelioma. Tüberküloz ve Toraks, 67, 162-168. [Google Scholar] [CrossRef] [PubMed]
[13] Manzini, V.P., Recchia, L., Cafferata, M., et al. (2010) Malignant Peritoneal Mesothelioma: A Multicenter Study on 81 Cases. Annals of Oncology, 1, 348-353. [Google Scholar] [CrossRef] [PubMed]
[14] Sauter, J.L., Dacic, S., Galateau-Salle, F., et al. (2022) The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. Journal of Thoracic Oncology, 7, 608-622. [Google Scholar] [CrossRef] [PubMed]
[15] Liu, S., Staats, P., Lee, M., et al. (2014) Diffuse Mesothelioma of the Peritoneum: Correlation between Histological and Clinical Parameters and Survival in 73 Patients. Pathology, 46, 604-609. [Google Scholar] [CrossRef
[16] Baratti, D., Kusamura, S., Cabras, A.D. and Deraco, M. (2012) Cytoreductive Surgery with Selective versus Complete Parietal Peritonectomy Followed by Hyperthermic Intra-peritoneal Chemotherapy in Patients with Diffuse Malignant Peritoneal Mesothelioma: A Controlled Study. Annals of Surgical Oncology, 19, 1416-1424. [Google Scholar] [CrossRef] [PubMed]
[17] Boussiosa, S., Moschettab, M., Karathanasia, A., et al. (2018) Malignant Peritoneal Mesothelioma: Clinical Aspects, and Therapeutic Perspectives. Annals of Gastroenterology, 31, 1-11. [Google Scholar] [CrossRef] [PubMed]
[18] Vogelzang, N.J., Rusthoven, J.J., Symanowski, J., et al. (2003) Phase Ⅲ Study of Pemetrexed in Combination with Cisplatin versus Cisplatin Alone in Patients with Malignant Pleural Mesothelioma. Journal of Clinical Oncology, 21, 2636-2644. [Google Scholar] [CrossRef
[19] 江路, 杨乐, 杨子萱, 等. 3例恶性腹膜间皮瘤的临床表现和基因突变特点分析及文献回顾[J]. 现代肿瘤医学, 2022, 30(13): 2415-2419.
[20] Schaub, N.P., Alimchandani, M., Quezado, M., et al. (2013) A Novel Nomogram for Perito-neal Mesothelioma Predicts Survival. Annals of Surgical Oncology, 20, 555-561. [Google Scholar] [CrossRef] [PubMed]
[21] Helm, J.H., Miura, J.T., Glenn, J.A., et al. (2015) Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 22, 1686-1693. [Google Scholar] [CrossRef] [PubMed]
[22] 杜雪梅, 李鑫宝, 孟巍, 等. 恶性腹膜间皮瘤100例临床病理特征及预后分析[J]. 中国肿瘤临床, 2023, 50(8): 403-410.